At Saince, we build the technological foundation that empowers providers to focus entirely on their patients. By seamlessly integrating artificial intelligence, cloud-native infrastructure, and deep system interoperability, we are eliminating inefficiencies and bringing clinical information, radiology, and hospital management into the modern era. We are not just a service provider—we are a high-tech innovation engine for the healthcare industry.

USA: 5490 McGinnis Village Place, Suite 116, Alpharetta, GA 30005.
+1 888 472 4623 | sales@saince.com
INDIA: Corporate Address: #6-3-1090, Ground Floor, Block B, TSR Towers, Raj Bhavan Road, Somajiguda, Hyderabad, Telangana 500082.
Registered Address: #202, Shatabdi Residency, Ramnagargundu, Hyderabad, Telangana 500044.
+91 40 6728 5555 | sales@saince.in
Contact Us
Address 5490 McGinnis Village Place, Suite 116, Alpharetta, GA 30005.
Follow Us

Clinical documentation, imaging and intelligence solutions.

Blog Details

Blogs
MRI, hybrid imaging outperform conventional tests for small cell lung cancer staging December 19, 2021

MRI, hybrid imaging outperform conventional tests for small cell lung cancer staging

FDG PET/CT, whole-body MRI, and coregistered FDG PET/MRI outperformed conventional tests for various staging endpoints in patients with SCLC," concluded first author Yoshiharu Ohno from the Fujita Health University School of Medicine in Japan. Whole-body MRI and FDG PET/MRI outperformed FDG PET/CT for T category and thus TNM stage, indicating the utility of MRI for assessing extent of local invasion in SCLC. MRI, with or without FDG PET coregistration, can improve the staging of patients with small-cell lung cancer.

These additional observations may relate to a superior role of MRI in assessing the extent of local soft-tissue invasion by tumor, as has been observed in settings other than SCLC.

Read more: https://www.sciencedaily.com/releases/2021/12/211209095634.htm